BRAF and glioma: We focused on genes mediating selumetinib sensitivity as potentially druggable dependencies, and the top 2 conserved sensitivity hits were BRAF, a direct effector of Ras with established roles in glioma (16, 17, 37), and SHOC2, which has not been previously implicated in glioblastoma to our knowledge (Figure 4C).